Head-To-Head Contrast: Advanced Medical Isotope (OTCMKTS:RDGL) vs. Trinity Capital (NASDAQ:TRIN)

Advanced Medical Isotope (OTCMKTS:RDGL) and Trinity Capital (NASDAQ:TRIN) are both small-cap finance companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Advanced Medical Isotope and Trinity Capital, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Medical Isotope	0	0	0	0	0.00
Trinity Capital	1	1	2	0	2.25

Trinity Capital has a consensus target price of $15.75, indicating a potential downside of 4.37%. Given Trinity Capital’s stronger consensus rating and higher probable upside, analysts plainly believe Trinity Capital is more favorable than Advanced Medical Isotope.

Profitability

This table compares Advanced Medical Isotope and Trinity Capital’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Advanced Medical Isotope	-6,401.92%	N/A	-139.36%
Trinity Capital	51.88%	15.72%	7.08%

Volatility and Risk

Advanced Medical Isotope has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Trinity Capital has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Earnings & Valuation

This table compares Advanced Medical Isotope and Trinity Capital”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Medical Isotope	$30,000.00	1,410.62	-$2.91 million	N/A	N/A
Trinity Capital	$203.47 million	5.69	$115.60 million	$2.23	7.39

Trinity Capital has higher revenue and earnings than Advanced Medical Isotope.

Insider and Institutional Ownership

24.6% of Trinity Capital shares are held by institutional investors. 18.5% of Advanced Medical Isotope shares are held by company insiders. Comparatively, 5.3% of Trinity Capital shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Trinity Capital beats Advanced Medical Isotope on 9 of the 12 factors compared between the two stocks.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

About Trinity Capital

Trinity Capital Inc. is a business development company. It is a venture capital firm specializing in venture debt to growth stage companies looking for loans and/or equipment financing. Trinity Capital Inc. was founded in 2019 is based in Phoenix, Arizona with additional offices in the United States.